Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Privia Health Group Inc (NASDAQ: PRVA) was $25.53 for the day, up 1.15% from the previous closing price of $25.24. In other words, the price has increased by $1.15 from its previous closing price. On the day, 0.74 million shares were traded. PRVA stock price reached its highest trading level at $25.8 during the session, while it also had its lowest trading level at $25.01.
Ratios:
Our analysis of PRVA’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.03 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 34.11. For the most recent quarter (mrq), Quick Ratio is recorded 1.65 and its Current Ratio is at 1.65. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Needham on January 10, 2025, initiated with a Buy rating and assigned the stock a target price of $25.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 13 ’25 when Mehrotra Parth sold 15,909 shares for $24.52 per share. The transaction valued at 390,089 led to the insider holds 407,234 shares of the business.
Mehrotra Parth sold 13,773 shares of PRVA for $344,187 on May 12 ’25. The Chief Executive Officer now owns 423,143 shares after completing the transaction at $24.99 per share. On May 12 ’25, another insider, Mountcastle David, who serves as the EVP & Chief Financial Officer of the company, sold 3,322 shares for $24.99 each. As a result, the insider received 83,017 and left with 172,909 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRVA now has a Market Capitalization of 3133295104 and an Enterprise Value of 2800503040. As of this moment, Privia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 218.39, and their Forward P/E ratio for the next fiscal year is 78.90. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.69. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.65 while its Price-to-Book (P/B) ratio in mrq is 4.59. Its current Enterprise Value per Revenue stands at 1.474 whereas that against EBITDA is 100.999.
Stock Price History:
The Beta on a monthly basis for PRVA is 0.83, which has changed by 0.4318564 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, PRVA has reached a high of $26.09, while it has fallen to a 52-week low of $17.40. The 50-Day Moving Average of the stock is 11.86%, while the 200-Day Moving Average is calculated to be 12.46%.
Shares Statistics:
PRVA traded an average of 919.61K shares per day over the past three months and 804410 shares per day over the past ten days. A total of 122.67M shares are outstanding, with a floating share count of 108.44M. Insiders hold about 11.64% of the company’s shares, while institutions hold 92.14% stake in the company. Shares short for PRVA as of 1759190400 were 3872515 with a Short Ratio of 4.21, compared to 1756425600 on 2957140. Therefore, it implies a Short% of Shares Outstanding of 3872515 and a Short% of Float of 5.6900002.
Earnings Estimates
. The current rating of Privia Health Group Inc (PRVA) is the result of assessments by 10.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.22, with high estimates of $0.25 and low estimates of $0.17.
Analysts are recommending an EPS of between $0.95 and $0.8 for the fiscal current year, implying an average EPS of $0.9. EPS for the following year is $1.01, with 10.0 analysts recommending between $1.14 and $0.79.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 14 analysts. It ranges from a high estimate of $517.2M to a low estimate of $477.25M. As of. The current estimate, Privia Health Group Inc’s year-ago sales were $437.92MFor the next quarter, 14 analysts are estimating revenue of $505.24M. There is a high estimate of $532M for the next quarter, whereas the lowest estimate is $483.22M.
A total of 14 analysts have provided revenue estimates for PRVA’s current fiscal year. The highest revenue estimate was $2.05B, while the lowest revenue estimate was $1.97B, resulting in an average revenue estimate of $2B. In the same quarter a year ago, actual revenue was $1.74BBased on 14 analysts’ estimates, the company’s revenue will be $2.19B in the next fiscal year. The high estimate is $2.38B and the low estimate is $2.13B.
